Cargando…

Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data

BACKGROUND: In 2011, Kenya introduced the 10-valent pneumococcal conjugate vaccine together with a catch-up campaign for children aged <5 years in Kilifi County. In a post-vaccination surveillance study based in Kilifi, there was a substantial decline in invasive pneumococcal disease (IPD). Howev...

Descripción completa

Detalles Bibliográficos
Autores principales: Ojal, John, Flasche, Stefan, Hammitt, Laura L., Akech, Donald, Kiti, Moses C., Kamau, Tatu, Adetifa, Ifedayo, Nurhonen, Markku, Scott, J. Anthony G., Auranen, Kari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571446/
https://www.ncbi.nlm.nih.gov/pubmed/28729018
http://dx.doi.org/10.1016/j.vaccine.2017.07.019
_version_ 1783259339982635008
author Ojal, John
Flasche, Stefan
Hammitt, Laura L.
Akech, Donald
Kiti, Moses C.
Kamau, Tatu
Adetifa, Ifedayo
Nurhonen, Markku
Scott, J. Anthony G.
Auranen, Kari
author_facet Ojal, John
Flasche, Stefan
Hammitt, Laura L.
Akech, Donald
Kiti, Moses C.
Kamau, Tatu
Adetifa, Ifedayo
Nurhonen, Markku
Scott, J. Anthony G.
Auranen, Kari
author_sort Ojal, John
collection PubMed
description BACKGROUND: In 2011, Kenya introduced the 10-valent pneumococcal conjugate vaccine together with a catch-up campaign for children aged <5 years in Kilifi County. In a post-vaccination surveillance study based in Kilifi, there was a substantial decline in invasive pneumococcal disease (IPD). However, given the continued circulation of the vaccine serotypes it is possible that vaccine-serotype disease may re-emerge once the effects of the catch-up campaign wear off. METHODS: We developed a compartmental, age-structured dynamic model of pneumococcal carriage and invasive disease for three serotype groups: the 10-valent vaccine serotypes and two groups of non-vaccine serotypes based on their susceptibility to mutual competition. The model was calibrated to age- and serotype-specific data on carriage and IPD in the pre-vaccination era and used to predict carriage prevalence and IPD up to ten years post-vaccination in Kilifi. The model was validated against the observed carriage prevalence after vaccine introduction. RESULTS: The model predicts a sustained reduction in vaccine-type pneumococcal carriage prevalence from 33% to 8% in infants and from 30% to 8% in 1–5 year olds over the 10-year period following vaccine introduction. The incidence of IPD is predicted to decline across all age groups resulting in an overall reduction of 56% in the population, corresponding to 10.4 cases per 100,000 per year. The vaccine-type IPD incidence is estimated to decline by 83% while non-vaccine-type IPD incidence is predicted to increase by 52%. The model's predictions of carriage prevalence agrees well with the observed data in the first five years post-vaccination. CONCLUSION: We predict a sustained and substantial decline in IPD through PCV vaccination and that the current regimen is insufficient to fully eliminate vaccine-serotype circulation in the model. We show that the observed impact is likely to be sustained despite waning effects of the catch-up campaign.
format Online
Article
Text
id pubmed-5571446
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier Science
record_format MEDLINE/PubMed
spelling pubmed-55714462017-08-30 Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data Ojal, John Flasche, Stefan Hammitt, Laura L. Akech, Donald Kiti, Moses C. Kamau, Tatu Adetifa, Ifedayo Nurhonen, Markku Scott, J. Anthony G. Auranen, Kari Vaccine Article BACKGROUND: In 2011, Kenya introduced the 10-valent pneumococcal conjugate vaccine together with a catch-up campaign for children aged <5 years in Kilifi County. In a post-vaccination surveillance study based in Kilifi, there was a substantial decline in invasive pneumococcal disease (IPD). However, given the continued circulation of the vaccine serotypes it is possible that vaccine-serotype disease may re-emerge once the effects of the catch-up campaign wear off. METHODS: We developed a compartmental, age-structured dynamic model of pneumococcal carriage and invasive disease for three serotype groups: the 10-valent vaccine serotypes and two groups of non-vaccine serotypes based on their susceptibility to mutual competition. The model was calibrated to age- and serotype-specific data on carriage and IPD in the pre-vaccination era and used to predict carriage prevalence and IPD up to ten years post-vaccination in Kilifi. The model was validated against the observed carriage prevalence after vaccine introduction. RESULTS: The model predicts a sustained reduction in vaccine-type pneumococcal carriage prevalence from 33% to 8% in infants and from 30% to 8% in 1–5 year olds over the 10-year period following vaccine introduction. The incidence of IPD is predicted to decline across all age groups resulting in an overall reduction of 56% in the population, corresponding to 10.4 cases per 100,000 per year. The vaccine-type IPD incidence is estimated to decline by 83% while non-vaccine-type IPD incidence is predicted to increase by 52%. The model's predictions of carriage prevalence agrees well with the observed data in the first five years post-vaccination. CONCLUSION: We predict a sustained and substantial decline in IPD through PCV vaccination and that the current regimen is insufficient to fully eliminate vaccine-serotype circulation in the model. We show that the observed impact is likely to be sustained despite waning effects of the catch-up campaign. Elsevier Science 2017-08-16 /pmc/articles/PMC5571446/ /pubmed/28729018 http://dx.doi.org/10.1016/j.vaccine.2017.07.019 Text en © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ojal, John
Flasche, Stefan
Hammitt, Laura L.
Akech, Donald
Kiti, Moses C.
Kamau, Tatu
Adetifa, Ifedayo
Nurhonen, Markku
Scott, J. Anthony G.
Auranen, Kari
Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data
title Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data
title_full Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data
title_fullStr Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data
title_full_unstemmed Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data
title_short Sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in Kilifi, Kenya: A mathematical model based on pre-vaccination data
title_sort sustained reduction in vaccine-type invasive pneumococcal disease despite waning effects of a catch-up campaign in kilifi, kenya: a mathematical model based on pre-vaccination data
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5571446/
https://www.ncbi.nlm.nih.gov/pubmed/28729018
http://dx.doi.org/10.1016/j.vaccine.2017.07.019
work_keys_str_mv AT ojaljohn sustainedreductioninvaccinetypeinvasivepneumococcaldiseasedespitewaningeffectsofacatchupcampaigninkilifikenyaamathematicalmodelbasedonprevaccinationdata
AT flaschestefan sustainedreductioninvaccinetypeinvasivepneumococcaldiseasedespitewaningeffectsofacatchupcampaigninkilifikenyaamathematicalmodelbasedonprevaccinationdata
AT hammittlaural sustainedreductioninvaccinetypeinvasivepneumococcaldiseasedespitewaningeffectsofacatchupcampaigninkilifikenyaamathematicalmodelbasedonprevaccinationdata
AT akechdonald sustainedreductioninvaccinetypeinvasivepneumococcaldiseasedespitewaningeffectsofacatchupcampaigninkilifikenyaamathematicalmodelbasedonprevaccinationdata
AT kitimosesc sustainedreductioninvaccinetypeinvasivepneumococcaldiseasedespitewaningeffectsofacatchupcampaigninkilifikenyaamathematicalmodelbasedonprevaccinationdata
AT kamautatu sustainedreductioninvaccinetypeinvasivepneumococcaldiseasedespitewaningeffectsofacatchupcampaigninkilifikenyaamathematicalmodelbasedonprevaccinationdata
AT adetifaifedayo sustainedreductioninvaccinetypeinvasivepneumococcaldiseasedespitewaningeffectsofacatchupcampaigninkilifikenyaamathematicalmodelbasedonprevaccinationdata
AT nurhonenmarkku sustainedreductioninvaccinetypeinvasivepneumococcaldiseasedespitewaningeffectsofacatchupcampaigninkilifikenyaamathematicalmodelbasedonprevaccinationdata
AT scottjanthonyg sustainedreductioninvaccinetypeinvasivepneumococcaldiseasedespitewaningeffectsofacatchupcampaigninkilifikenyaamathematicalmodelbasedonprevaccinationdata
AT auranenkari sustainedreductioninvaccinetypeinvasivepneumococcaldiseasedespitewaningeffectsofacatchupcampaigninkilifikenyaamathematicalmodelbasedonprevaccinationdata